Etanercept (Enbrel): update on therapeutic use - Wikidata - awgldk - TriplyDB

Etanercept (Enbrel): update on therapeutic use

Etanercept (Enbrel): update on therapeutic use

http://www.wikidata.org/entity/Q34071287

about

Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy Rheumatoid arthritis as a hyper-endoplasmic-reticulum-associated degradation disease Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors.Etanercept biosimilars Role of interleukin 18 in rheumatoid arthritis.Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.TNFalpha blockade in human diseases: mechanisms and future directions.Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis.Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus.Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules

P2860

Q24684755-8AB62335-209B-40E5-9AD1-A1F20269EBA2 Q24812528-859E92D9-E0E8-4BA2-9D75-E499A4F5D1F6 Q33371239-B9CC7D4B-52BA-402D-ACF2-9D4392114104 Q35020358-8768D0BD-4C29-4114-99DD-0C64F9C70AFA Q35553488-0CE6FC89-6BCC-4A59-AC06-AAFA57F100BB Q36052572-676B95B2-A173-43E8-B277-3F6EFDBE67F9 Q36094915-A3E737D8-5D6B-496B-842C-6BEC123A1ED6 Q36536886-2E6CEF0E-6F1A-4F6E-B07A-211EA3ADBEDB Q36648407-90ED2354-7601-4EB4-BE97-FC433D8D1ED0 Q36916918-34CEB9D0-C685-405E-8BBB-0E36DBBE16DE Q37023883-32C8C7FE-5F08-447D-8900-EB579B5238FA Q42735592-2D9EDC24-77BB-45E4-AEC8-2FA659D454A6 Q56990581-6CEA7C6B-8C18-4544-BC00-B807DF86A19F

P2860

Etanercept (Enbrel): update on therapeutic use

http://www.wikidata.org/entity/Q34071287

description

2000 nî lūn-bûn

@nan

2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Etanercept (Enbrel): update on therapeutic use

@ast

Etanercept (Enbrel): update on therapeutic use

@en

type

label

Etanercept (Enbrel): update on therapeutic use

@ast

Etanercept (Enbrel): update on therapeutic use

@en

prefLabel

Etanercept (Enbrel): update on therapeutic use

@ast

Etanercept (Enbrel): update on therapeutic use

@en

P1433

Q34071287-992DE212-3513-4069-B03A-E6EE0C259AB7

P1476

Q34071287-33BA3DF8-A069-4B05-AC76-77CA4ECB421B

P2093

Q34071287-C9FA41A0-B401-42CC-A9F3-BFF4946E7D65

P2860

Q34071287-145D0F73-D49C-4C94-B1BC-B0D08ABBED29

Q34071287-4926CDEA-E552-469B-AACA-09B9F1D4ECD2

Q34071287-7E3E9B28-6B82-4AC1-9035-FD6BBFB032E1

Q34071287-935D1AC0-0EDA-4DED-B840-BFC6FB2170A9

Q34071287-96290009-2DD1-4330-8F89-D393D257D0B8

Q34071287-97E9A043-DF18-4B87-BE12-0C2D8AEDDD63

Q34071287-AEC3AA73-80AF-436E-AD3C-8A8462BC6E3D

Q34071287-B244928E-EA48-4B2D-9A5B-EA4DEACACB58

Q34071287-D720B6DD-3260-48AF-8513-856C39D2CFD4

Q34071287-DA4C9227-56EF-4001-B816-8F63ACB2FC50

P304

Q34071287-9B8D5AD0-DCC1-484C-87BC-72896AD5AE09

P31

Q34071287-9B19455B-AD4F-4388-9D35-E888C92452F1

P356

Q34071287-24B0B0DF-BACC-41FC-B78A-CA8341532289

P407

Q34071287-821EC116-4791-4E66-8E09-0000A97CC366

P478

Q34071287-0539DA06-756D-42C8-8862-97AD30FEA590

P577

Q34071287-66725A3C-21D1-48B8-94DC-72FB80B8A87F

P5875

Q34071287-32F03907-7799-44BD-A840-1D322D820486

P698

Q34071287-E72B2126-937C-4E87-999B-09FD4998C868

P932

Q34071287-170BBE9D-33D0-4D34-BD4A-D3662E4BD45D

P356

ARD.59.SUPPL_1.I46

P1433

Annals of the Rheumatic Diseases

P1476

Etanercept (Enbrel): update on therapeutic use

@en

P2093

Spencer-Green G

http://www.w3.org/2001/XMLSchema#string

P2860

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts

Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1

Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro.

Cancer statistics, 1997.

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

P304

i46-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.59.SUPPL_1.I46

http://www.w3.org/2001/XMLSchema#string

P407

P478

59 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2000-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12273765

http://www.w3.org/2001/XMLSchema#string

P698

11053088

http://www.w3.org/2001/XMLSchema#string

P932

1766625

http://www.w3.org/2001/XMLSchema#string